Financial Data and Key Metrics Changes - For the full year 2025, revenue increased by 40.5% to $82 million, net income rose by 98% to $7.6 million, and adjusted EBITDA increased by 107% to $19.9 million [3][4] - Operating margins improved by 723 basis points, indicating a significant inflection point for future revenue growth and profitability [4][18] Business Line Data and Key Metrics Changes - The patient affordability business saw annual revenue growth of 168%, reaching $33.9 million compared to $12.7 million in 2024, with claims processed increasing by approximately 79% [4][16] - Plasma donor compensation revenue increased by 4% to $45.6 million, driven by the addition of 115 net plasma centers, despite a decline in average plasma donations per center [13][17] Market Data and Key Metrics Changes - The company has active programs with six of the top 10 U.S. pharmaceutical manufacturers ranked by revenue, indicating strong market penetration [6] - The patient affordability platform delivered nearly $1 billion in financial assistance to patients, supporting access to high-cost therapies for over 840,000 individuals [4] Company Strategy and Development Direction - The company aims to leverage its dynamic business rules technology to help pharmaceutical manufacturers manage co-pay assistance programs more effectively, which is a key value proposition [5][11] - The company is focused on expanding its patient affordability business, which is expected to remain the primary driver of growth moving into 2026 [15][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the patient affordability business, indicating that they are still in the early stages of this opportunity [14][15] - The company anticipates revenue for 2026 to be between $106.5 million and $110.5 million, representing a year-over-year growth of 30%-35% [21][22] Other Important Information - The company exited 2025 with $21.1 million in cash, nearly double from the prior year, and continues to have zero bank debt [20] - The company is actively working on integrating its donor management system with plasmapheresis devices, which is expected to enhance operational efficiency [14] Q&A Session Summary Question: Observations on Pharma Manufacturers' Activity - Management noted that there is no slowdown in activity among pharmaceutical manufacturers, with strong pipelines and ongoing investments in innovation [27][28] Question: GLP-1 Products on the Platform - The company does not currently have major GLP-1 products but is making efforts to penetrate that market, particularly in diabetes [30] Question: Fixed Costs and Operating Leverage - Management clarified that fixed costs are expected to plateau, with a significant reduction in incremental costs as the business grows [32][34] Question: Revenue Growth Drivers for Plasma Business - Revenue growth in the plasma business is anticipated due to increased collection efficiencies and the addition of new centers [51] Question: Competitive Landscape and Market Position - Management emphasized that the company is well-positioned in a competitive landscape, leveraging its unique offerings and technology to differentiate itself [66][70] Question: Concerns About AI and Competitive Advantages - Management does not view AI as a threat but rather as an opportunity to enhance their algorithms and improve service offerings [92][93]

Financial Data and Key Metrics Changes - For the full year 2025, revenue increased by 40.5% to $82 million, net income rose by 98% to $7.6 million, and adjusted EBITDA increased by 107% to $19.9 million [3][4] - Operating margins improved by 723 basis points, indicating a significant inflection point for future revenue growth and profitability [4][18] Business Line Data and Key Metrics Changes - The Patient Affordability business saw annual revenue growth of 168%, reaching $33.9 million compared to $12.7 million in 2024, with claims processed increasing by approximately 79% [4][16] - Plasma donor compensation revenue increased by 4% to $45.6 million, driven by the addition of 115 net plasma centers, despite a decline in average plasma donations per center [13][17] Market Data and Key Metrics Changes - The company has active programs with six of the top 10 U.S. pharmaceutical manufacturers ranked by revenue, indicating strong market penetration [6] - The Patient Affordability platform helped deliver nearly $1 billion in financial assistance to over 840,000 individuals in 2025 [4] Company Strategy and Development Direction - The company aims to continue scaling its Patient Affordability business, which has become a central driver of growth and profitability, while also maintaining a stable plasma business [14][15] - The focus remains on enhancing the dynamic business rules technology to provide better economic value for pharmaceutical manufacturers [5][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the Patient Affordability business, expecting continued momentum into 2026 with revenue guidance of $106.5 million to $110.5 million [21][22] - The company does not foresee significant threats from legislative changes or competition, viewing current dynamics as reinforcing the need for their solutions [11][24] Other Important Information - The company exited 2025 with $21.1 million in cash, nearly double from the prior year, and has zero bank debt [20] - The outlook for 2026 includes expectations for gross profit margins between 60%-62% and operating expenses to increase by 20% [22][23] Q&A Session Summary Question: Observations on pharma manufacturers' recent activity - Management noted no slowdown in activity among pharma manufacturers, citing strong pipelines and ongoing investments in innovation [26][27] Question: GLP-1 products on the platform - Currently, the company does not have major GLP-1 products but is actively pursuing opportunities in that market [29][30] Question: Insights on fixed costs and operating leverage - Management indicated that fixed costs are expected to plateau, with a focus on controlling SG&A growth to enhance operating leverage [32][33] Question: Pipeline for patient affordability programs - Management refrained from providing specific guidance on the pipeline at this early stage but indicated that evaluations would occur after key industry conferences [75][79] Question: Investor understanding of the business model - Management acknowledged that there is a need to better communicate the co-pay model and the unique advantages of their offerings to investors [80][86]

Company Overview - Longevity Health Holdings, Inc. focuses on human longevity and healthy aging, recently announcing a merger with True Health Inc., a key player in the plasma collection industry [1][2] - True Health operates under the THPlasma brand and has established a growing network of plasma collection centers in the Northeast United States [7] Merger Details - The merger is an all-stock transaction, with the combined company expected to continue trading on Nasdaq under the symbol "XAGE" [1] - The merger follows Longevity's previous acquisitions of Carmell Therapeutics and Elevai Skincare, enhancing its capabilities in plasma-derived growth factors and exosomes [2] Industry Context - The United States supplies over 60% of the world's plasma but faces a shortfall in plasma and plasma-derived therapeutics, creating a significant market opportunity for THPlasma [3] - THPlasma is addressing this shortfall with a rapidly expanding footprint of plasma collection centers [3] Financial Highlights - THPlasma has guaranteed sales offtake agreements for up to $100 million annually and achieved cash profitability in FY2024 [8] - Projected FY2025 revenue for THPlasma is estimated at $10 million, with EBITDA of $2 million and net income of $1 million, while FY2026 estimates show revenue growth to $32 million, EBITDA of $7 million, and net income of $4 million [8] Strategic Vision - The merger is expected to unlock access to public markets and future M&A opportunities, with both companies' leadership expressing optimism about growth and value creation [6][8] - Longevity aims to drive further growth in THPlasma through both acquisitions and organic growth strategies [6]

Financial Data and Key Metrics Changes - For the full year 2024, revenue increased by 23.5% to $58.4 million, and adjusted EBITDA increased by 43.3% to $9.6 million [8] - Adjusted EBITDA margins improved by 230 basis points to 16.5% [8] - Fourth quarter total revenues of $15.6 million increased by $1.9 million or 14% compared to the same period last year [21] - Net income for the fourth quarter was $1.4 million or $0.02 per fully diluted share, down from $5.6 million or $0.05 per fully diluted share in the same period last year [23] Business Line Data and Key Metrics Changes - The patient affordability business grew 212% year-over-year, reaching $12.7 million compared to $4.1 million in 2023 [9] - Claims processed in the patient affordability segment increased by 272%, with 33 net programs added, representing a 77% increase over the previous year [9] - Plasma donor compensation business contributed $43.9 million in revenue for the year, a 4.6% increase over 2023's $42 million [11] - Fourth quarter plasma revenue decreased by 6.2% to $10.8 million, primarily due to oversupply issues [18] Market Data and Key Metrics Changes - The company exited 2024 with 480 plasma centers, an increase of 16 centers over the previous year, and anticipates adding 10 to 15 centers in 2025 [11] - The average revenue per plasma center decreased by 9.5% to $7,510 [18] - Fourth quarter pharma revenues of $12.7 million accounted for 21.7% of total revenue, up from 8.6% during the same period last year [20] Company Strategy and Development Direction - The long-term strategy focuses on expanding solutions to create new revenue streams, particularly in maturing segments [13] - The acquisition of Gamma Innovation LLC aims to enhance capabilities in plasma donor and pharmaceutical patient engagement [14] - The company plans to enter the high-margin software-as-a-service market, significantly expanding its total addressable market [14] Management's Comments on Operating Environment and Future Outlook - Management expects the patient affordability business to sustain its strong growth trajectory in 2025, projecting to at least double in revenue [10] - The plasma business is facing challenges due to oversupply and increased donation yields, which are expected to persist [12] - Guidance for 2025 anticipates total revenues between $68.5 million and $70 million, reflecting year-over-year growth of 17.5% to 20% [26] Other Important Information - The company exited the year with $10.8 million in unrestricted cash and zero debt, a decrease of $6.3 million from 2023 [24] - The company repurchased 36,700 shares in the fourth quarter for approximately $135,000 [25] Q&A Session Summary Question: Can you help us understand the strength in Q4 and the contributions from existing vs. new pharma patient affordability programs? - Management noted that 14 new programs were launched in the first quarter of 2025, with 10 added in Q4 2024, indicating strong revenue visibility from historical programs [35][37] Question: What is the marketing strategy behind the Gamma acquisition? - The acquisition is aimed at enhancing engagement tools and capabilities for both plasma and pharmaceutical businesses, with no revenue from Gamma factored into guidance [39][41] Question: Can you provide a deeper dive into the issues causing the slowdown in the plasma business? - Management explained that oversupply is due to post-COVID overproduction and increased plasma yields, leading to lower donations and compensation [50][51] Question: How many new programs are anticipated in the patient affordability segment this year? - Management indicated that they aim to at least double the number of programs added last year, with 14 already added in Q1 2025 [66] Question: Can you quantify the cash portion of the purchase price related to Gamma? - The cash portion will be paid out over five years, with the company maintaining a cautious approach to its cash position [73]